Skip to main content
Erschienen in: Urolithiasis 4/2010

01.08.2010 | Symposium paper

Brushite stone disease as a consequence of lithotripsy?

verfasst von: Amy E. Krambeck, Shelly E. Handa, Andrew P. Evan, James E. Lingeman

Erschienen in: Urolithiasis | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

The incidence of calcium phosphate (CaP) stone disease has increased over the last three decades; specifically, brushite stones have been diagnosed and treated more frequently than in previous years. Brushite is a unique form of CaP, which in certain patients can form into large symptomatic stones. Treatment of brushite stones can be difficult since the stones are resistant to shock wave and ultrasonic lithotripsy, and often require ballistic fragmentation. Patients suffering from brushite stone disease are less likely to be rendered stone free after surgical intervention and often experience stone recurrence despite maximal medical intervention. Studies have demonstrated an association between brushite stone disease and shock wave lithotripsy (SWL) treatment. Some have theorized that many brushite stone formers started as routine calcium oxalate (CaOx) stone formers who sustained an injury to the nephron (such as SWL). The injury to the nephron leads to failure of urine acidification and eventual brushite stone formation. We explore the association between brushite stone disease and iatrogenic transformation of CaOx stone disease to brushite by reviewing the current literature.
Literatur
1.
Zurück zum Zitat Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC (2003) Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 63:1817–1823CrossRefPubMed Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC (2003) Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 63:1817–1823CrossRefPubMed
2.
Zurück zum Zitat Pearle MS, Calhoun EA, Curhan GC (2005) Urologic diseases in America project: urolithiasis. J Urol 173:848–857CrossRefPubMed Pearle MS, Calhoun EA, Curhan GC (2005) Urologic diseases in America project: urolithiasis. J Urol 173:848–857CrossRefPubMed
3.
Zurück zum Zitat Scales CD Jr, Curtis LH et al (2007) Changing gender prevalence of stone disease. J Urol 177:979–982CrossRefPubMed Scales CD Jr, Curtis LH et al (2007) Changing gender prevalence of stone disease. J Urol 177:979–982CrossRefPubMed
4.
Zurück zum Zitat VanDervoort K, Wjesen J, Frank R, Vento S, Crosby V, Chandra M, Trachtman H (2007) Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome. J Urol 177:2300–2305CrossRefPubMed VanDervoort K, Wjesen J, Frank R, Vento S, Crosby V, Chandra M, Trachtman H (2007) Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome. J Urol 177:2300–2305CrossRefPubMed
5.
Zurück zum Zitat Parks JH, Worcester EM, Coe FL, Evan AP, Lingeman JE (2004) Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int 66:777–785CrossRefPubMed Parks JH, Worcester EM, Coe FL, Evan AP, Lingeman JE (2004) Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int 66:777–785CrossRefPubMed
6.
Zurück zum Zitat Mandel N, Mandel I, Fryjoff K, Rejniak T, Mandel G (2003) Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes. J Urol 169:2026–2029CrossRefPubMed Mandel N, Mandel I, Fryjoff K, Rejniak T, Mandel G (2003) Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes. J Urol 169:2026–2029CrossRefPubMed
7.
Zurück zum Zitat Parks JH, Coe FL, Evan AP, Worcester EM (2009) Urine pH in renal calcium stone formers who do and do not increase stone phosphate content with time. Nephrol Dial Transplant 24:130–136CrossRefPubMed Parks JH, Coe FL, Evan AP, Worcester EM (2009) Urine pH in renal calcium stone formers who do and do not increase stone phosphate content with time. Nephrol Dial Transplant 24:130–136CrossRefPubMed
8.
Zurück zum Zitat Matlaga BR, Kim SC, Watkins SL, Kuo RL, Munch LC, Lingeman JE (2006) Changing composition of renal calculi in patients with neurogenic bladder. J Urol 175:1716–1719CrossRefPubMed Matlaga BR, Kim SC, Watkins SL, Kuo RL, Munch LC, Lingeman JE (2006) Changing composition of renal calculi in patients with neurogenic bladder. J Urol 175:1716–1719CrossRefPubMed
9.
Zurück zum Zitat Pak CY, Poindexter JR, Adams-Huet B, Pearle MS (2003) Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med 115:26–32CrossRefPubMed Pak CY, Poindexter JR, Adams-Huet B, Pearle MS (2003) Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med 115:26–32CrossRefPubMed
10.
Zurück zum Zitat Kuo RL, Moran ME, Kim DH, Abrahams HM, White MD, Lingeman JE (2002) Topiramate-induced nephrolithiasis. J Endourol 16:229–231CrossRefPubMed Kuo RL, Moran ME, Kim DH, Abrahams HM, White MD, Lingeman JE (2002) Topiramate-induced nephrolithiasis. J Endourol 16:229–231CrossRefPubMed
11.
Zurück zum Zitat Matlaga BR, Coe FL, Evan AP, Lingeman JE (2007) The role of Randall’s plaques in the pathogenesis of calcium stones. J Urol 177:31–38CrossRefPubMed Matlaga BR, Coe FL, Evan AP, Lingeman JE (2007) The role of Randall’s plaques in the pathogenesis of calcium stones. J Urol 177:31–38CrossRefPubMed
12.
Zurück zum Zitat Neman WF, Toribara TY, Mulryan BJ (1962) Synthetic hydroxyapatite crystals. 1. Sodium and potassium fixation. Arch Biochem Biophys 98:384–390CrossRefPubMed Neman WF, Toribara TY, Mulryan BJ (1962) Synthetic hydroxyapatite crystals. 1. Sodium and potassium fixation. Arch Biochem Biophys 98:384–390CrossRefPubMed
13.
Zurück zum Zitat Pak CY, Eanes ED, Ruskin B (1971) Spontaneous precipitation of brushite in urine: evidence that brushite is the nidus of renal stones originating as calcium phosphate. Proc Nat Acad Sci 68:1456–1460CrossRefPubMed Pak CY, Eanes ED, Ruskin B (1971) Spontaneous precipitation of brushite in urine: evidence that brushite is the nidus of renal stones originating as calcium phosphate. Proc Nat Acad Sci 68:1456–1460CrossRefPubMed
14.
Zurück zum Zitat Krambeck AE, Handa SE, Coe FL, Worchester EM, Evan AP, Lingeman JE (2010) Profile of the brushite stone former. J Urol (Under review) Krambeck AE, Handa SE, Coe FL, Worchester EM, Evan AP, Lingeman JE (2010) Profile of the brushite stone former. J Urol (Under review)
15.
Zurück zum Zitat Gault MH, Parfrey PS, Robertson WG (1988) Idiopathic calcium phosphate nephrolithiasis. Nephron 48:265–273CrossRefPubMed Gault MH, Parfrey PS, Robertson WG (1988) Idiopathic calcium phosphate nephrolithiasis. Nephron 48:265–273CrossRefPubMed
16.
Zurück zum Zitat Evan AP, Lingeman JE, Coe FL, Shao Y, Parks JH, Bledsoe SB et al (2005) Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int 67:576–591CrossRefPubMed Evan AP, Lingeman JE, Coe FL, Shao Y, Parks JH, Bledsoe SB et al (2005) Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int 67:576–591CrossRefPubMed
17.
Zurück zum Zitat Klee LW, Brito CG, Lingeman JE (1991) The clinical implications of brushite calculi. J Urol 145:715–718PubMed Klee LW, Brito CG, Lingeman JE (1991) The clinical implications of brushite calculi. J Urol 145:715–718PubMed
18.
Zurück zum Zitat Heimbach D, Jacobs D, Hesse A, Muller SC, Zhong P, Preminger GM (1999) How to improve lithotripsy and chemolitholysis of brushite-stones: an in vitro study. Urol Res 27:266–271CrossRefPubMed Heimbach D, Jacobs D, Hesse A, Muller SC, Zhong P, Preminger GM (1999) How to improve lithotripsy and chemolitholysis of brushite-stones: an in vitro study. Urol Res 27:266–271CrossRefPubMed
19.
Zurück zum Zitat Kacker R, Meeks JJ, Zhao L, Nadler RB (2008) Decreased stone-free rates after percutaneous nephrolithotomy for high calcium phosphate composition kidney stones. J Urol 180:958–960CrossRefPubMed Kacker R, Meeks JJ, Zhao L, Nadler RB (2008) Decreased stone-free rates after percutaneous nephrolithotomy for high calcium phosphate composition kidney stones. J Urol 180:958–960CrossRefPubMed
20.
Zurück zum Zitat Kuo RL, Lingeman JE, Evan AP, Paterson RF, Parks JH, Bledsoe SB et al (2003) Urine calcium and volume predict coverage of renal papilla by Randall’s plaque. Kidney Int 64:2150–2155CrossRefPubMed Kuo RL, Lingeman JE, Evan AP, Paterson RF, Parks JH, Bledsoe SB et al (2003) Urine calcium and volume predict coverage of renal papilla by Randall’s plaque. Kidney Int 64:2150–2155CrossRefPubMed
21.
Zurück zum Zitat Kaude JV, Williams CM, Millner MR, Scott KN, Finlayson B (1985) Renal morphology and function immediately after extracorporeal shock wave lithotripsy. Am J Roentgenol 145:305–313 Kaude JV, Williams CM, Millner MR, Scott KN, Finlayson B (1985) Renal morphology and function immediately after extracorporeal shock wave lithotripsy. Am J Roentgenol 145:305–313
22.
Zurück zum Zitat Connors BA, Evan AP, Willis LR, Blomgren PM, Lingeman JE, Fineberg NS (2000) The effect of discharge voltage on renal injury and impairment caused by lithotripsy in the pig. J Am Soc Nephrol 11:310–318PubMed Connors BA, Evan AP, Willis LR, Blomgren PM, Lingeman JE, Fineberg NS (2000) The effect of discharge voltage on renal injury and impairment caused by lithotripsy in the pig. J Am Soc Nephrol 11:310–318PubMed
23.
Zurück zum Zitat Evan AP, Willis LR, Lingeman JE, McAteer JA (1998) Renal trauma and the risk of long-term complications in shock wave lithotripsy. Nephron 78:1–8 Evan AP, Willis LR, Lingeman JE, McAteer JA (1998) Renal trauma and the risk of long-term complications in shock wave lithotripsy. Nephron 78:1–8
24.
Zurück zum Zitat Hamm LL, Alpern R (1980) Cellular mechanisms of renal tubular acidification. In: Seldin DW, Giebisch G (eds) The kidney: physiology and pathophysiology, 2nd edn. Raven Press, New York, p 2581 Hamm LL, Alpern R (1980) Cellular mechanisms of renal tubular acidification. In: Seldin DW, Giebisch G (eds) The kidney: physiology and pathophysiology, 2nd edn. Raven Press, New York, p 2581
25.
Zurück zum Zitat Krambeck AE, Gettman MT, Rohlinger AL, Lohse CM, Patterson DE, Segura JW (2006) Diabetes mellitus and hypertension associated with shock wave lithotripsy at 19 years follow-up. J Urol 175:1742–1747CrossRefPubMed Krambeck AE, Gettman MT, Rohlinger AL, Lohse CM, Patterson DE, Segura JW (2006) Diabetes mellitus and hypertension associated with shock wave lithotripsy at 19 years follow-up. J Urol 175:1742–1747CrossRefPubMed
Metadaten
Titel
Brushite stone disease as a consequence of lithotripsy?
verfasst von
Amy E. Krambeck
Shelly E. Handa
Andrew P. Evan
James E. Lingeman
Publikationsdatum
01.08.2010
Verlag
Springer-Verlag
Erschienen in
Urolithiasis / Ausgabe 4/2010
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-010-0289-y

Weitere Artikel der Ausgabe 4/2010

Urolithiasis 4/2010 Zur Ausgabe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.